QuVa Pharma

As a 503B outsourcing facility, QuVa can manufacture large, non-patient-specific batches of sterile injectables under FDA-registered cGMP standards. This allows it to supply thousands of hospitals with ready-to-administer drugs — a scale that traditional patient-specific compounding pharmacies cannot achieve. The 503B framework also subjects QuVa to FDA inspection, creating a manufacturing-quality bar above state-regulated 503A pharmacies.

The July 2024 acquisition of BrightStream Health introduced an AI-powered analytics layer that ingests data from over 350 datasets across health-system sites. Branded as QuVa BrightStream, the unit targets hospital-pharmacy performance, drug-shortage prediction, and medication-use analytics. It transforms QuVa from a pure-product supplier into a combined drug-plus-intelligence partner for health systems.

QuVa's product list includes controlled substances like low-dose fentanyl in preservative-free syringes with a 90-day beyond-use date, CADD cassettes with tamper-evident packaging, and cardioplegia solutions such as del Nido. The firm focuses on essential, shortage-prone, ready-to-administer medications that hospitals need in predictable, shelf-stable formats.

QuVa states it serves over 3,000 U.S. hospitals. It distributes products through a combination of direct-shipment and forward-distribution centers that the firm calls 'industry-first remote direct distribution capabilities.' No geographic breakdown or international presence is publicly disclosed.

Legally, it operates as a 503B sterile-outsourcing manufacturer. Operationally, it spans all three: it runs FDA-registered drug-production lines, compounds on a non-patient-specific basis under cGMP, and now sells AI-driven hospital-pharmacy analytics through its QuVa BrightStream unit following the 2024 BrightStream acquisition.